A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens.

Nasopharyngeal cancer (NPC) is a prevalent type of cancer that often takes the form of undifferentiated carcinoma in the Maghreb region. It affects people of all ages. NPC diagnosis, mainly based on detecting Epstein-Barr virus (EBV), has not been well evaluated in North Africa. We compared the classical EBV serological tests using indirect immunofluorescence to the detection of EBV DNase antibodies by immunoblot in Algerian NPC patients. Significant variations were observed among different age groups of patients regarding the presence of VCA-IgA antibodies (0-14 and ≥30 years old, p < 0.0001; 15-19 and ≥30 years old, p < 0.01) and EA-IgA (0-14 and ≥30 years old, p < 0.01; 15-29 and ≥30 years old, p < 0.05). Differences were also noted in the titers of IgA anti-VCA and anti-EA antibodies across the three age groups. Some patients under the age of 30 with detectable IgG anti-VCA antibodies had undetectable IgA anti-VCA antibodies. These patients had a strong anti-DNase IgA response. However, older individuals had a higher level of anti-DNase IgG. Before treatment, children had strong DNase reactivity as indicated by specific IgA antibodies. Young adults had high IgA anti-DNase response, but the elderly (90.9%) had a lower response for these antibodies. Following therapy, the children retained high levels of IgA anti-DNase antibodies, and 66% of the young adults demonstrated robust antibody reactivity against DNase. In contrast, IgG responses to anti-DNase were low in children. This study demonstrated the utility of anti-DNase responses in the diagnosis and prognosis of NPC.

Study of Serum Carcinoembryonic Antigen's Profile for Breast Cancer in Western Algeria: 100 cases.

BACKGROUND: Breast cancer is the most common cancer in women worldwide. Biology contributes to the early diagnosis and monitoring of breast cancer with several categories of markers such as prognostic markers (ER, PR, HER2), proliferative markers (Ki67), and tumor markers such as CEA and CA 15-3. CEA can be detected at a high concentration in serum of patients with malignant tumors. AIM: The aim of our study was to evaluate the concentrations of CEA in serum of women with breast cancer and to verify the existence of a possible link between the average rates of CEA and SBR grade. METHODS: Serum samples from 100 patients with breast cancer and 100 controls was recovered and examined with an AxSYM analyzer (Abbott Laboratories, USA) to measure CEA using Microparticle Enzyme Immunoassay (MEIA) technology. RESULTS: In our clinical study, the mean age of patients and controls were 52.7 and 50.3 years respectively. The results revealed an elevation in the CEA levels from patients with an average value of 16.61 ± 0.2 ng/ml. Positive correlation was found between CEA concentrations and SBR grade, it has found with 45,7 ± 1 ng/ml in grade III. CONCLUSION: CEA represents an excellent marker for breast cancer development. Changes in its concentration reflect the effectiveness or ineffectiveness of treatment.

Assessment of hypoxic stress in 44 women with breast cancer in the West Algeria.

AIM: The objective of this study was to evaluate the expression of hypoxia-inducible transcription factor 1α (HIF1α) protein profile among women with breast cancer in a population of western Algerian and to correlate the intensity of this expression with prognosis histological grade Scarff Bloom and Richardson (SBR) of the disease and the age of the patients. METHODS: We used a kit provided by Life Science Inc (UScnk) for a sandwich enzyme immunoassay for the quantitative measurement of in vitro HIF1α in plasma in 44 patients and 44 controls in a population of western Algerian. Then we looked for the correlation between the intensity of the expression of HIF1α and prognosis histological grade SBR and the age of the patients studied. RESULTS: The results indicate high levels of HIF1α at SBRIII grade with an average value of 12.26 ± 0.5 ng/ml. The average age of patients is around 50 ± 1year. In healthy subjects the mean concentration of 1.88 ± 0.1 ng/ml represents HIF1α with a mean age of 49 ± 1year. CONCLUSION: Clinical monitoring of patients treated for breast cancer by assaying the HIF1α marker seems to be very important in the prognosis.